Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoTSE:4521 +1.04%69 EBITDA Margin % is 19.05% as of Mar. 2026, which is 26% below its 10-year median of 25.71. GuruFocus rates TSE:4521 with a GF Score™ of 69/100 and a GF Value™ of 円3,775.44 (Fairly Valued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks worse than 62.46% on this metric.
Kaken Pharmaceutical Co (TSE:4521) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kaken Pharmaceutical Co EBITDA Margin % Related Terms
Kaken Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (TSE:4521) has a EBITDA Margin % of 19.05% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kaken Pharmaceutical Co and its competitors. This is 26% below median its historical median of 25.71. Over the past decade, Kaken Pharmaceutical Co's EBITDA Margin % has ranged from 7.39 to 32.41. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #599 out of 959 companies in the Drug Manufacturers industry, placing it in the top 62.5%.
Is Kaken Pharmaceutical Co's EBITDA Margin % too high?
Kaken Pharmaceutical Co's current EBITDA Margin % of 19.05% is 26% below median its 10-year median of 25.71. Over the past 10 years, this metric has ranged from a low of 7.39 to a high of 32.41. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Kaken Pharmaceutical Co's value of 19.05% is 51.9% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #599 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #599 out of 959 companies for EBITDA Margin %. This places Kaken Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Kaken Pharmaceutical Co's value of 19.05% is 51.9% above this benchmark. Historically, Kaken Pharmaceutical Co's own EBITDA Margin % has ranged from 7.39 to 32.41 over the past decade. While the company's 10-year median is 25.71 vs. the industry median of 12.54, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current EBITDA Margin % of 19.05% is 51.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current EBITDA Margin % is 19.05%, which is 26% below median its own 10-year median of 25.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,775.44, compared to a current price of 円3,900.00 — trading 3.3% above its estimated fair value. The current EBITDA Margin % is 19.05%, which is 26% below median its 10-year median of 25.71 and 51.9% above the Drug Manufacturers industry median of 12.54. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current EBITDA Margin % is 19.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,900.00 is trading 3.3% above its estimated GF Value™ of 円3,775.44.
GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4521:
EBITDA Margin %: 19.05% (26% below median its 10-year median of 25.71)
GF Value™: 円3,775.44 vs. price of 円3,900.00 (3.3% above fair value)
Industry Position: 51.9% above the Drug Manufacturers median (#599 of 959)
No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for TSE:4521
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4521 has been successfully added to your 
